Benralizumab for the Prevention of COPD Exacerbations

QR kód

Benralizumab for the Prevention of COPD Exacerbations

The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.In the GALATHEA and TERRANOVA trials, we enrolled p...

Teljes leírás

Elmentve itt :

Bibliográfiai részletek
Szerzők:	Criner Gerard J Celli Bartolome R Brightling Christopher E Agusti Alvar Papi Alberto Singh Dave Sin Don D Vogelmeier Claus F Sciurba Frank C Bafadhel Mona Backer Vibeke Kato Motokazu Ramírez-Venegas Alejandra Wei Yu-Feng Bjermer Leif Shih Vivian H Jison Maria O'Quinn Sean Makulova Natalya Newbold Paul Goldman Mitchell Martin Ubaldo J Kollaborációs szervezet: GALATHEA Study Investigators Kollaborációs szervezet: TERRANOVA Study Investigators Bálint Beatrix
Dokumentumtípus:	Cikk
Megjelent:	2019
Sorozat:	NEW ENGLAND JOURNAL OF MEDICINE 381 No. 11
Tárgyszavak:	Klinikai orvostan
doi:	10.1056/NEJMoa1905248
mtmt:	31168405
Online Access:	http://publicatio.bibl.u-szeged.hu/29946

Hasonló tételek

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021 a systematic analysis for the Global Burden of Disease Study 2021 /
Szerző: Kollaborációs szervezet: GBD 2021 Risk Factors Collaborators, et al.
Megjelent: (2024)

A comparison of the antimicrobial resistance of fecal Bacteroides isolates and assessment of the composition of the intestinal microbiotas of carbapenem-treated and non-treated persons from Belgium and Hungary
Szerző: Sóki József, et al.
Megjelent: (2021)

The International Collaboration to Improve Respiratory Health in Children (INCIRCLE) ERS Clinical Research Collaboration
Szerző: Sly Peter D., et al.
Megjelent: (2018)

Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC)
Szerző: Ramlakhan Karishma P., et al.
Megjelent: (2021)

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
Szerző: Roe Matthew T, et al.
Megjelent: (2019)

Effect of Alirocumab on Mortality After Acute Coronary Syndromes
Szerző: Steg Philippe Gabriel, et al.
Megjelent: (2019)

Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial
Szerző: Szarek Michael, et al.
Megjelent: (2019)

The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics
Szerző: Jardine Meg J., et al.
Megjelent: (2017)

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Szerző: Mahaffey Kenneth W., et al.
Megjelent: (2019)

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial /
Szerző: Jukema J. Wouter, et al.
Megjelent: (2019)

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) secondary analysis of a randomised, phase 3 trial /
Szerző: Trotman Judith, et al.
Megjelent: (2018)

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Szerző: Wedzicha JA, et al.
Megjelent: (2016)

Which extent of surgical resection thoracic surgeons would choose if they were diagnosed with an early-stage lung cancer a European survey /
Szerző: Brunelli Alessandro, et al.
Megjelent: (2024)

Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma
Szerző: Pistoni Laura, et al.
Megjelent: (2021)

Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease
Szerző: Campens Laurence, et al.
Megjelent: (2021)

Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Szerző: Vogelmeier Claus, et al.
Megjelent: (2011)

Machine learning identifies a common signature for anti-SSA/Ro60 antibody expression across autoimmune diseases
Szerző: Foulquier Nathan, et al.
Megjelent: (2022)

Antimicrobial resistance surveillance of Bacteroides fragilis isolated from blood cultures, Europe, 2022 (ReSuBacfrag)
Szerző: Buhl Michael E. J., et al.
Megjelent: (2024)

Contemporary Presentation and Management of Valvular Heart Disease The EURObservational Research Programme Valvular Heart Disease II Survey
Szerző: Iung Bernard, et al.
Megjelent: (2019)

Cohort profile the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry /
Szerző: Nadarajah Ramesh, et al.
Megjelent: (2023)

Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?
Szerző: Ariotti Sara, et al.
Megjelent: (2016)

Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease An ECCO CONFER Case Series /
Szerző: Phillips Frank, et al.
Megjelent: (2022)

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis
Szerző: Paller Amy S., et al.
Megjelent: (2022)

Key influences of VDD (DX) ICD selection Results from a prospective, national survey /
Szerző: Vámos Máté, et al.
Megjelent: (2024)

Long-term adjunctive lacosamide treatment in patients with partial-onset seizures
Szerző: Rosenow Felix, et al.
Megjelent: (2016)

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators two randomised clinical trials /
Szerző: Fabbri Leonardo M, et al.
Megjelent: (2009)

Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates
Szerző: Valgimigli Marco, et al.
Megjelent: (2015)

Coronary-artery bypass surgery in patients with left ventricular dysfunction
Szerző: Velazquez Eric J, et al.
Megjelent: (2011)

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema 1‑year results from the Japan subgroup of the phase 3 YOSEMITE trial /
Szerző: Shimura Masahiko, et al.
Megjelent: (2023)

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study) a randomised, placebo-controlled study /
Szerző: Maher Toby M, et al.
Megjelent: (2019)

Tiotropium Respimat Inhaler and the Risk of Death in COPD
Szerző: Wise Robert A, et al.
Megjelent: (2013)

Feasibility of PET/CT system performance harmonisation for quantitative multicentre Zr-89 studies
Szerző: Kaalep Andres, et al.
Megjelent: (2018)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases A European retrospective observational study /
Szerző: Goessens Laurent, et al.
Megjelent: (2021)

Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997-2017
Szerző: Versporten Ann, et al.
Megjelent: (2021)

Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997-2017
Szerző: Adriaenssens Niels, et al.
Megjelent: (2021)

Consumption of penicillins in the community, European Union/European Economic Area, 1997-2017
Szerző: Bruyndonckx Robin, et al.
Megjelent: (2021)

Bilastine for the treatment of allergic rhinoconjunctivitis and urticaria results from an international Delphi study /
Szerző: Canonica Giorgio Walter, et al.
Megjelent: (2024)

Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis
Szerző: Miehlke Stephan, et al.
Megjelent: (2018)

A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci
Szerző: Martin Jose-Ezequiel, et al.
Megjelent: (2013)

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) a randomised, phase 3, open-label, multicentre study /
Szerző: Dimopoulos Meletios A., et al.
Megjelent: (2016)